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Surgeons treating breast cancer patients make
repeated decisions as they select from an array of
complex management options. The end point of any
recommendation to our patients is, do the potential
beneﬁts of surgery outweigh the potential risks?
Whether to perform an axillary lymphadenectomy
and whether to go ahead with autologous tissue-
based immediate breast reconstructive surgery
immediately after total mastectomy is determined by
intraoperative evaluation of the sentinel node or
nodes removed from the axilla.
Regarding the decisions surrounding the staging
and treatment of axillary lymph nodes, the elements
of decision making on the beneﬁts side include: (1)
the goals of surgery (diagnosis of metastases, regional
disease control, and increasing survival rates), (2)
staging information on the natural history of disease
that aﬀects survival outcomes (e.g., number of nodal
metastases, extracapsular invasion), and (3) improved
cosmetic and rehabilitation beneﬁts of immediate
breast reconstruction using autologous ﬂaps. The
elements of decision making on the risk side include:
(1) the morbidity of a level I and II lymphadenectomy
(e.g., wound complications, lymphedema, numbness),
(2) patient comorbidity risk factors (e.g., obesity,
older age), (3) risk of not performing a lymphade-
nectomy, which may increase the future risk of
regional recurrence, and (4) the risk of poor outcome
after reconstruction followed by irradiation to the
reconstructed breast.
One central component of this decision-making is
getting complete and reliable information on the
status of nodal metastases, which in turn inﬂuences
intraoperative decisions on whether to perform a
more complete lymphadenectomy and decisions on
the type of immediate breast reconstructive surgery.
The staging information regarding nodal status will
also inﬂuence postoperative decisions regarding the
type and intensity of adjuvant systemic therapy and
the deployment of adjuvant radiation therapy to the
remaining axillary/supraclavicular lymph nodes and
the chest wall.
Some tenets of lymph nodes metastases are being
reexamined as sentinel lymph node (SLN) technology
is increasingly being used in the staging of and
treatment planning for breast cancer and melanoma.
Samoilova et al.1 ask a provocative question: is it
necessary to perform a more complete axillary node
dissection in patients with small micrometastases in
the SLN? Alternatively, could the treatment safely be
limited to the sentinel node excision or a limited
dissection of level I lymph nodes? And what is the
lower threshold of metastatic cells in a SLN for which
we should stage patients as N+ instead of N(mic), or
dismiss the ﬁnding as isolated tumor cells of no
clinical signiﬁcance?
One of the important questions addressed in this
study is whether any factors would predict an inci-
dence of four or more metastatic nodes for which
adjuvant radiation therapy would be indicated and
for which extensive reconstructive breast surgery
might have to be deferred until this is completed. The
authors performed a retrospective review of 467
patients who underwent SLN biopsy, 126 (27%) of
whom were found to have metastases in the SLN.
They then correlated clinicopathological variables
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with the incidence of ﬁnding additional metastases in
non-SLNs after an axillary lymphadenectomy. The
authors performed a careful evaluation of the SLN
by studying 2-mm intervals by examination of both
frozen sections and hematoxylin and eosin–stained
samples. In this study, any evidence of tumor cells
within the sentinel node on hematoxylin and eosin
stain was recorded as a disease-positive node.
Patients with a disease-positive SLN underwent
completion lymphadenectomy. Approximately 20%
of the SLN-positive patients (and 5% of all patients)
had more than three metastatic nodes (N2–3). The
measured dimensions of the nodal metastases were
the prognostic variable that most reliably separated
N1a from N2–3 patients. All patients with sentinel
node deposits <5 mm had three or fewer metastatic
nodes, and 91% had a single nodal metastases. As the
authors state in this retrospective study, this infor-
mation could be valuable in making intraoperative
decisions as to whether it would be safe to perform a
limited node dissection, or even no further surgical
excision other than excision of the SLNs.
The authors state that a complete axillary lym-
phadenectomy ‘‘is associated with signiﬁcant mor-
bidity: lymphedema is reported in 13% to 50%,
sensory loss in 31%, and overall arm edema in 38%
of patients.’’ Understanding morbidity risks when
making intraoperative decisions is important infor-
mation in assessing the risk-beneﬁt ratio of lym-
phadenectomy. But we believe these estimates
overstate the morbidity risks in the current era of
breast surgery. The risk-beneﬁt analysis must also
include the risk of the SLN procedure and the future
risk to the patient if an axillary recurrence does
occur. The best risk analysis of the SLN procedure
comes from the American College of the Surgeons
Oncology Group Z0010 data, which showed a 6.9%
incidence of arm swelling (change from baseline arm
circumference of >2 cm) at 6 months after sur-
gery—a risk greater than was anticipated. The sen-
tinel node procedure also carries a risk of axillary
seroma of 7.1%, hematoma 1.4%, wound infection
1%, axillary paresthesias 8.6%, and decreased range
of motion 3.8%. These risks are reported with 6
months of follow-up, but the long-term eﬀects are
currently unknown.2
How solid is the evidence that a more complete
lymphadenectomy fulﬁlls the goals of staging and
treatment? How solid is the evidence that selective
lymphadenectomy of the nodes surrounding the
SLN fulﬁlls the goals of staging and treatment? If
limited lymph node dissection is completed and the
disease recurs in the axilla, what are the treatment
options, and what is the morbidity associated with
these options? We do not know the recurrence
rates when a limited dissection is completed. What
is the morbidity of these limited dissections? What
is the nerve injury rate, and what is the lymphe-
dema rate?
What is the evidence of increased risk after a more
complete lymphadenectomy? Publication of the
ALMANAC trial demonstrates an increased risk of
axillary dissection over SLN biopsy.3 However, the
clinical signiﬁcance of the absolute risks documented
in that study are not known. Investigation into the
use of more limited nodal dissection (levels I/II) must
include the impact on morbidity and risk of relapse in
an era of micrometastases?
What is the evidence that irradiation after breast
reconstructive surgery causes tissue distortions and
poor outcomes? What is the inﬂuence of speciﬁc
ﬁndings on frozen-section examination of the sentinel
node in patients undergoing total mastectomy and
the number of metastatic nodes on intraoperative
decisions to proceed with axillary dissection, autolo-
gous tissue reconstruction, and postoperative irradi-
ation? Should plans continue for immediate breast
reconstruction, and should it inﬂuence the type of
reconstruction used?
The authors have concluded that sentinel node
patients with tumor deposits of <5 mm will only
have a 5% incidence of non-SLN metastases and
that there is a 91% probability of a single node
involvement. From this retrospective data, they
concluded that such patients may be considered for
a limited node dissection—limited to sentinel nodes
only and/or a selective axillary dissection of only
the nodes immediately adjacent to the SLN. We
believe this is a spurious conclusion because the
denominator of patients to be compared is really
the 27% of patients who had a metastatic sentinel
node, not the entire group of patients undergoing a
SLN procedure, including those who were SLN
negative. The more representative incidence on
more than three metastatic nodes (N2–3) is 19%
(24 of 126 SLN-positive patients). This higher
incidence mitigates the argument that one could
forego a more complete lymphadenectomy because
of the risk that patients might be understaged, and
therefore undertreated, if they did not have a level I
and II lymphadenectomy. Nevertheless, it does
provide an important hypothesis to test in pro-
spective clinical trials on the natural history of
small micrometastases.
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If there is no therapeutic beneﬁt for complete lym-
phadenectomy in SLN-positive patients, then the
primary value of the procedure is staging. If the results
from this retrospective study were conﬁrmed by a
prospective study, then this group of patients with tiny
metastases might be able to join those who are sentinel
node negative and be spared the additional treatment
and associated morbidity of a more complete lym-
phadenectomy. On the other hand, we have an obli-
gation to prove that we can provide more conservative
treatment safely, so this study cannot be used to alter
what is today considered the standard of care.
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